A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer
- 13.01.2022
- Original Article
Erschienen in:
- Verfasst von
- Bangyou Zuo
- Xiaobo Yang
- Xu Yang
- Jin Bian
- Junyu Long
- Dongxu Wang
- Cong Ning
- Yanyu Wang
- Ziyu Xun
- Yunchao Wang
- Xin Lu
- Yilei Mao
- Xinting Sang
- Haitao Zhao
- Erschienen in
- Cancer Immunology, Immunotherapy | Ausgabe 8/2022
Abstract
Background
Anti-PD-1 antibodies plus lenvatinib therapeutic regimens have demonstrated a relatively high antitumor response in many solid cancers; however, the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer (GBC) has not been reported.
Methods
Advanced GBC patients who received anti-PD-1 antibodies plus lenvatinib were retrospectively screened. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR), PD-L1 expression and safety were evaluated to identify efficacy biomarkers.
Results
A total of 31 GBC patients were included in this study. After a median follow-up of 8 months and 23 deaths were observed. The median PFS was 5.0 months (95% CI: 4.1–8.0 months), and the median OS was 11.3 months (95% CI: 7.5–20.9 months). Overall, the ORR was 32.3%, the DCR was 83.9%, and the CBR was 41.9%. Moreover, after treatment, 3 patients received conventional surgery, in which 1 patient achieved a pathological complete response. All patients (100%) experienced adverse events (AEs), and 58.1% of the patients experienced grade 3 AEs. The most commonly observed grade 3 AEs included fatigue (5/31, 16.1%), decreased appetite (5/31, 16.1%), hypertension (4/31, 12.9%) and bilirubin elevation (4/31, 12.9%). Subgroup analysis revealed that positive PD-L1 expression maybe associate with a longer PFS.
Conclusion
Anti-PD-1 antibodies plus lenvatinib represent an effective and tolerable therapy for patients with advanced gallbladder cancer.
Anzeige
- Titel
- A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer
- Verfasst von
-
Bangyou Zuo
Xiaobo Yang
Xu Yang
Jin Bian
Junyu Long
Dongxu Wang
Cong Ning
Yanyu Wang
Ziyu Xun
Yunchao Wang
Xin Lu
Yilei Mao
Xinting Sang
Haitao Zhao
- Publikationsdatum
- 13.01.2022
- Verlag
- Springer Berlin Heidelberg
- Erschienen in
-
Cancer Immunology, Immunotherapy / Ausgabe 8/2022
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851 - DOI
- https://doi.org/10.1007/s00262-021-03121-0
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
